Email
Print
Anti-Obesity Drugs Market Overview:
The Anti-Obesity Drugs Market size is estimated to reach $xx Million by 2030, growing at a CAGR of xx% during the forecast period 2023-2030. The global anti-obesity drugs market has experienced growth driven by the escalating prevalence of obesity worldwide. This health challenge is linked to various chronic conditions, including diabetes and cardiovascular diseases, emphasizing the demand for effective weight management solutions. Anti-obesity drugs are classified into different categories, including appetite suppressants and lipase inhibitors, each targeting specific aspects of weight control. While some medications require prescriptions, others are available over the counter, catering to diverse patient needs.
Despite growth opportunities, the market faces challenges such as safety concerns, potential side effects, and the need for sustained efficacy, prompting ongoing research and development efforts. Key pharmaceutical players specializing in metabolic disorders contribute significantly to the market's evolution by introducing novel medications and enhancing existing formulations. Regional variations in market dynamics exist, influenced by healthcare infrastructure, cultural attitudes toward body weight, and lifestyle factors. As the global awareness of obesity-related health risks continues to rise, the anti-obesity drugs market is poised for further developments and innovations in the quest for effective and safe weight management solutions.
Market Snapshot:
Anti-Obesity Drugs Market - Report Coverage:
The “Anti-Obesity Drugs Market Report - Forecast (2023-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Anti-Obesity Drugs Market.
Anti-Obesity Drugs Market - Top Trends
Focus on Combination Therapies: Pharmaceutical companies were exploring and developing combination therapies, combining different mechanisms of action to enhance the effectiveness of anti-obesity drugs. This approach aimed to address multiple aspects of weight regulation simultaneously.
Advancements in Mechanisms of Action: Research and development efforts were directed towards discovering and understanding new mechanisms of action for anti-obesity drugs. This included drugs targeting specific receptors or pathways in the body involved in appetite regulation and metabolism.
Personalized Medicine Approaches: There was a growing interest in personalized medicine within the anti-obesity drugs market. Tailoring treatments based on individual patient characteristics, such as genetics or metabolic profile, aimed to improve drug efficacy and reduce the risk of adverse effects.
Rise of GLP-1 Receptor Agonists: Glucagon-like peptide-1 (GLP-1) receptor agonists were gaining prominence in the anti-obesity drugs market. Originally developed for diabetes management, these drugs showed weight loss benefits and were being explored for their potential in obesity treatment.
Digital Health Integration: Increasingly, digital health tools and technologies were being integrated into anti-obesity treatment strategies. This included mobile apps for tracking dietary habits, exercise, and medication adherence, providing a more comprehensive approach to weight management.
The Anti-Obesity Drugs Market - Company Analysis
Novo Nordisk A/S: Novo Nordisk is a major player in the field of diabetes care, and it has a presence in the obesity treatment market. Semaglutide, a GLP-1 receptor agonist initially developed for diabetes, showed promise in promoting weight loss and was being investigated for obesity management.
Arena Pharmaceuticals, Inc.: Arena Pharmaceuticals is a biopharmaceutical company with a focus on developing novel drugs for various therapeutic areas, including metabolic diseases. Belviq (lorcaserin) was one of Arena's anti-obesity medications, though it was withdrawn from the market in 2020.
Roche Holdings AG: Roche is a global pharmaceutical company involved in various therapeutic areas, including obesity. Orlistat, a lipase inhibitor marketed under the brand name Xenical, is one of Roche's medications for weight management.
Vivus, Inc.: Vivus is known for its focus on obesity and metabolic diseases. The company developed and marketed Qsymia (phentermine/topiramate), an FDA-approved prescription medication for weight management.
Nalpropion Pharmaceuticals: Nalpropion is a specialty pharmaceutical company that focuses on the development and commercialization of medications for the treatment of obesity. Their product, Contrave (naltrexone/bupropion), is an FDA-approved prescription medication for weight management.
Key Market Players:
Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies players in the Anti-Obesity Drugs Market adopt. The top 10 companies in Anti-Obesity Drugs Market are listed below:
1. Alizyme Plc
2. Arena Pharmaceuticals, Inc
3. Boehringer Ingelheim Gmbh
4. F. Hoffmann-La Roche Ltd
5. Glaxosmithkline Plc
6. Merck Co., Inc
7. Norgine B V
8. Novo Nordisk A/S
9. Pfizer Inc
10. Shionogi Inc
Scope of the Report:
For more Lifesciences and Healthcare Market reports, please click here
1. Anti-Obesity Drugs Market - Overview
1.1 Definitions and Scope
2. Anti-Obesity Drugs Market - Executive summary
2.1 Market Revenue, Market Size and Key Trends by Company
2.2 Key Trends by type of Application
2.3 Key Trends segmented by Geography
3. Anti-Obesity Drugs Market
3.1 Comparative analysis
3.1.1 Product Benchmarking - Top 10 companies
3.1.2 Top 5 Financials Analysis
3.1.3 Market Value split by Top 10 companies
3.1.4 Patent Analysis - Top 10 companies
3.1.5 Pricing Analysis
4. Anti-Obesity Drugs Market - Startup companies Scenario Premium
4.1 Top 10 startup company Analysis by
4.1.1 Investment
4.1.2 Revenue
4.1.3 Market Shares
4.1.4 Market Size and Application Analysis
4.1.5 Venture Capital and Funding Scenario
5. Anti-Obesity Drugs Market - Industry Market Entry Scenario Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis - Top 10 companies
6. Anti-Obesity Drugs Market Forces
6.1 Drivers
6.2 Constraints
6.3 Challenges
6.4 Porters five force model
6.4.1 Bargaining power of suppliers
6.4.2 Bargaining powers of customers
6.4.3 Threat of new entrants
6.4.4 Rivalry among existing players
6.4.5 Threat of substitutes
7. Anti-Obesity Drugs Market -Strategic analysis
7.1 Value chain analysis
7.2 Opportunities analysis
7.3 Product life cycle
7.4 Suppliers and distributors Market Share
8. Anti-Obesity Drugs Market - By Product Type (Market Size -$Million / $Billion)
8.1 Market Size and Market Share Analysis
8.2 Application Revenue and Trend Research
8.3 Product Segment Analysis
8.3.1 Prescription Drug
8.3.2 Otc Drug
9. Anti-Obesity Drugs Market - By Drug Class (Market Size -$Million / $Billion
9.1 Peripherally Acting Anti-Obesity Drug
9.2 Centrally Acting Anti-Obesity Drug
10. Anti-Obesity Drugs - By Medication (Market Size -$Million / $Billion)
10.1 Monotherapies
11.1 Anti-Obesity Drugs Market - North America Segment Research
11.2 North America Market Research (Million / $Billion)
11.2.1 Segment type Size and Market Size Analysis
11.2.2 Revenue and Trends
11.2.3 Application Revenue and Trends by type of Application
11.2.4 Company Revenue and Product Analysis
11.2.5 North America Product type and Application Market Size
11.2.5.1 U.S
11.2.5.2 Canada
11.2.5.3 Mexico
11.2.5.4 Rest of North America
11.3 Anti-Obesity Drugs- South America Segment Research
11.4 South America Market Research (Market Size -$Million / $Billion)
11.4.1 Segment type Size and Market Size Analysis
11.4.2 Revenue and Trends
11.4.3 Application Revenue and Trends by type of Application
11.4.4 Company Revenue and Product Analysis
11.4.5 South America Product type and Application Market Size
11.4.5.1 Brazil
11.4.5.2 Venezuela
11.4.5.3 Argentina
11.4.5.4 Ecuador
11.4.5.5 Peru
11.4.5.6 Colombia
11.4.5.7 Costa Rica
11.4.5.8 Rest of South America
11.5 Anti-Obesity Drugs- Europe Segment Research
11.6 Europe Market Research (Market Size -$Million / $Billion)
11.6.1 Segment type Size and Market Size Analysis
11.6.2 Revenue and Trends
11.6.3 Application Revenue and Trends by type of Application
11.6.4 Company Revenue and Product Analysis
11.6.5 Europe Segment Product type and Application Market Size
11.6.5.1 U.K
11.6.5.2 Germany
11.6.5.3 Italy
11.6.5.4 France
11.6.5.5 Netherlands
11.6.5.6 Belgium
11.6.5.7 Denmark
11.6.5.8 Spain
11.6.5.9 Rest of Europe
11.7 Anti-Obesity Drugs - APAC Segment Research
11.8 APAC Market Research (Market Size -$Million / $Billion)
11.8.1 Segment type Size and Market Size Analysis
11.8.2 Revenue and Trends
11.8.3 Application Revenue and Trends by type of Application
11.8.4 Company Revenue and Product Analysis
11.8.5 APAC Segment - Product type and Application Market Size
11.8.5.1 China
11.8.5.2 Australia
11.8.5.3 Japan
11.8.5.4 South Korea
11.8.5.5 India
11.8.5.6 Taiwan
11.8.5.7 Malaysia
11.8.5.8 Hong kong
11.8.5.9 Rest of APAC
11.9 Anti-Obesity Drugs - Middle East Segment and Africa Segment Research
11.10 Middle East & Africa Market Research (Market Size -$Million / $Billion)
11.10.1 Segment type Size and Market Size Analysis
11.10.2 Revenue and Trend Analysis
11.10.3 Application Revenue and Trends by type of Application
11.10.4 Company Revenue and Product Analysis
11.10.5 Middle East Segment Product type and Application Market Size
11.10.5.1 Israel
11.10.5.2 Saudi Arabia
11.10.5.3 UAE
11.10.6 Africa Segment Analysis
11.10.6.1 South Africa
11.10.6.2 Rest of Middle East & Africa
12. Anti-Obesity Drugs Market - Entropy
12.1 New product launches
12.2 M&A s, collaborations, JVs and partnerships
13. Anti-Obesity Drugs Market - Industry / Segment Competition landscape Premium
13.1 Market Share Analysis
13.1.1 Market Share by Country- Top companies
13.1.2 Market Share by Region- Top 10 companies
13.1.3 Market Share by type of Application - Top 10 companies
13.1.4 Market Share by type of Product / Product category- Top 10 companies
13.1.5 Market Share at global level - Top 10 companies
13.1.6 Best Practises for companies
14. Anti-Obesity Drugs Market - Key Company List by Country Premium
15. Anti-Obesity Drugs Market Company Analysis
15.1 Market Share, Company Revenue, Products, M&A, Developments
15.2 Alizyme Plc
15.3 Arena Pharmaceuticals, Inc
15.4 Boehringer Ingelheim Gmbh
15.5 F. Hoffmann-La Roche Ltd
15.6 Glaxosmithkline Plc
15.7 Merck Co., Inc
15.8 Norgine B V
15.9 Novo Nordisk A/S
15.10 Pfizer Inc
15.11 Shionogi Inc
15.12 Company 11
15.13 Company 12 & More
16.1 Abbreviations
16.2 Sources
17. Anti-Obesity Drugs Market - Methodology
17.1 Research Methodology
17.1.1 Company Expert Interviews
17.1.2 Industry Databases
17.1.3 Associations
17.1.4 Company News
17.1.5 Company Annual Reports
17.1.6 Application Trends
17.1.7 New Products and Product database
17.1.8 Company Transcripts
17.1.9 R&D Trends
17.1.10 Key Opinion Leaders Interviews
17.1.11 Supply and Demand Trends
1.1 Definitions and Scope
2. Anti-Obesity Drugs Market - Executive summary
2.1 Market Revenue, Market Size and Key Trends by Company
2.2 Key Trends by type of Application
2.3 Key Trends segmented by Geography
3. Anti-Obesity Drugs Market
3.1 Comparative analysis
3.1.1 Product Benchmarking - Top 10 companies
3.1.2 Top 5 Financials Analysis
3.1.3 Market Value split by Top 10 companies
3.1.4 Patent Analysis - Top 10 companies
3.1.5 Pricing Analysis
4. Anti-Obesity Drugs Market - Startup companies Scenario Premium
4.1 Top 10 startup company Analysis by
4.1.1 Investment
4.1.2 Revenue
4.1.3 Market Shares
4.1.4 Market Size and Application Analysis
4.1.5 Venture Capital and Funding Scenario
5. Anti-Obesity Drugs Market - Industry Market Entry Scenario Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis - Top 10 companies
6. Anti-Obesity Drugs Market Forces
6.1 Drivers
6.2 Constraints
6.3 Challenges
6.4 Porters five force model
6.4.1 Bargaining power of suppliers
6.4.2 Bargaining powers of customers
6.4.3 Threat of new entrants
6.4.4 Rivalry among existing players
6.4.5 Threat of substitutes
7. Anti-Obesity Drugs Market -Strategic analysis
7.1 Value chain analysis
7.2 Opportunities analysis
7.3 Product life cycle
7.4 Suppliers and distributors Market Share
8. Anti-Obesity Drugs Market - By Product Type (Market Size -$Million / $Billion)
8.1 Market Size and Market Share Analysis
8.2 Application Revenue and Trend Research
8.3 Product Segment Analysis
8.3.1 Prescription Drug
8.3.2 Otc Drug
9. Anti-Obesity Drugs Market - By Drug Class (Market Size -$Million / $Billion
9.1 Peripherally Acting Anti-Obesity Drug
9.2 Centrally Acting Anti-Obesity Drug
10. Anti-Obesity Drugs - By Medication (Market Size -$Million / $Billion)
10.1 Monotherapies
10.2 Polytherapies
11. Anti-Obesity Drugs- By Geography (Market Size -$Million / $Billion)11.1 Anti-Obesity Drugs Market - North America Segment Research
11.2 North America Market Research (Million / $Billion)
11.2.1 Segment type Size and Market Size Analysis
11.2.2 Revenue and Trends
11.2.3 Application Revenue and Trends by type of Application
11.2.4 Company Revenue and Product Analysis
11.2.5 North America Product type and Application Market Size
11.2.5.1 U.S
11.2.5.2 Canada
11.2.5.3 Mexico
11.2.5.4 Rest of North America
11.3 Anti-Obesity Drugs- South America Segment Research
11.4 South America Market Research (Market Size -$Million / $Billion)
11.4.1 Segment type Size and Market Size Analysis
11.4.2 Revenue and Trends
11.4.3 Application Revenue and Trends by type of Application
11.4.4 Company Revenue and Product Analysis
11.4.5 South America Product type and Application Market Size
11.4.5.1 Brazil
11.4.5.2 Venezuela
11.4.5.3 Argentina
11.4.5.4 Ecuador
11.4.5.5 Peru
11.4.5.6 Colombia
11.4.5.7 Costa Rica
11.4.5.8 Rest of South America
11.5 Anti-Obesity Drugs- Europe Segment Research
11.6 Europe Market Research (Market Size -$Million / $Billion)
11.6.1 Segment type Size and Market Size Analysis
11.6.2 Revenue and Trends
11.6.3 Application Revenue and Trends by type of Application
11.6.4 Company Revenue and Product Analysis
11.6.5 Europe Segment Product type and Application Market Size
11.6.5.1 U.K
11.6.5.2 Germany
11.6.5.3 Italy
11.6.5.4 France
11.6.5.5 Netherlands
11.6.5.6 Belgium
11.6.5.7 Denmark
11.6.5.8 Spain
11.6.5.9 Rest of Europe
11.7 Anti-Obesity Drugs - APAC Segment Research
11.8 APAC Market Research (Market Size -$Million / $Billion)
11.8.1 Segment type Size and Market Size Analysis
11.8.2 Revenue and Trends
11.8.3 Application Revenue and Trends by type of Application
11.8.4 Company Revenue and Product Analysis
11.8.5 APAC Segment - Product type and Application Market Size
11.8.5.1 China
11.8.5.2 Australia
11.8.5.3 Japan
11.8.5.4 South Korea
11.8.5.5 India
11.8.5.6 Taiwan
11.8.5.7 Malaysia
11.8.5.8 Hong kong
11.8.5.9 Rest of APAC
11.9 Anti-Obesity Drugs - Middle East Segment and Africa Segment Research
11.10 Middle East & Africa Market Research (Market Size -$Million / $Billion)
11.10.1 Segment type Size and Market Size Analysis
11.10.2 Revenue and Trend Analysis
11.10.3 Application Revenue and Trends by type of Application
11.10.4 Company Revenue and Product Analysis
11.10.5 Middle East Segment Product type and Application Market Size
11.10.5.1 Israel
11.10.5.2 Saudi Arabia
11.10.5.3 UAE
11.10.6 Africa Segment Analysis
11.10.6.1 South Africa
11.10.6.2 Rest of Middle East & Africa
12. Anti-Obesity Drugs Market - Entropy
12.1 New product launches
12.2 M&A s, collaborations, JVs and partnerships
13. Anti-Obesity Drugs Market - Industry / Segment Competition landscape Premium
13.1 Market Share Analysis
13.1.1 Market Share by Country- Top companies
13.1.2 Market Share by Region- Top 10 companies
13.1.3 Market Share by type of Application - Top 10 companies
13.1.4 Market Share by type of Product / Product category- Top 10 companies
13.1.5 Market Share at global level - Top 10 companies
13.1.6 Best Practises for companies
14. Anti-Obesity Drugs Market - Key Company List by Country Premium
15. Anti-Obesity Drugs Market Company Analysis
15.1 Market Share, Company Revenue, Products, M&A, Developments
15.2 Alizyme Plc
15.3 Arena Pharmaceuticals, Inc
15.4 Boehringer Ingelheim Gmbh
15.5 F. Hoffmann-La Roche Ltd
15.6 Glaxosmithkline Plc
15.7 Merck Co., Inc
15.8 Norgine B V
15.9 Novo Nordisk A/S
15.10 Pfizer Inc
15.11 Shionogi Inc
15.12 Company 11
15.13 Company 12 & More
*Financials would be provided on a best efforts basis for private companies
16. Anti-Obesity Drugs Market - Appendix16.1 Abbreviations
16.2 Sources
17. Anti-Obesity Drugs Market - Methodology
17.1 Research Methodology
17.1.1 Company Expert Interviews
17.1.2 Industry Databases
17.1.3 Associations
17.1.4 Company News
17.1.5 Company Annual Reports
17.1.6 Application Trends
17.1.7 New Products and Product database
17.1.8 Company Transcripts
17.1.9 R&D Trends
17.1.10 Key Opinion Leaders Interviews
17.1.11 Supply and Demand Trends
LIST OF TABLES
1.Global Global Anti-Obesity Drug Market, By Drug Class Market 2019-2024 ($M)1.1 Peripherally Acting Anti-Obesity Drug Market 2019-2024 ($M) - Global Industry Research
1.2 Centrally Acting Anti-Obesity Drug Market 2019-2024 ($M) - Global Industry Research
2.Global Global Anti-Obesity Drug Market, By Medication Market 2019-2024 ($M)
2.2 Polytherapies Market 2019-2024 ($M) - Global Industry Research
3.Global Global Anti-Obesity Drug Market, By Type Market 2019-2024 ($M)
3.1 Prescription Drug Market 2019-2024 ($M) - Global Industry Research
3.2 Otc Drug Market 2019-2024 ($M) - Global Industry Research
4.Global Global Anti-Obesity Drug Market, By Drug Class Market 2019-2024 (Volume/Units)
4.1 Peripherally Acting Anti-Obesity Drug Market 2019-2024 (Volume/Units) - Global Industry Research
4.2 Centrally Acting Anti-Obesity Drug Market 2019-2024 (Volume/Units) - Global Industry Research
5.Global Global Anti-Obesity Drug Market, By Medication Market 2019-2024 (Volume/Units)
5.2 Polytherapies Market 2019-2024 (Volume/Units) - Global Industry Research
6.Global Global Anti-Obesity Drug Market, By Type Market 2019-2024 (Volume/Units)
6.1 Prescription Drug Market 2019-2024 (Volume/Units) - Global Industry Research
6.2 Otc Drug Market 2019-2024 (Volume/Units) - Global Industry Research
7.North America Global Anti-Obesity Drug Market, By Drug Class Market 2019-2024 ($M)
7.1 Peripherally Acting Anti-Obesity Drug Market 2019-2024 ($M) - Regional Industry Research
7.2 Centrally Acting Anti-Obesity Drug Market 2019-2024 ($M) - Regional Industry Research
8.North America Global Anti-Obesity Drug Market, By Medication Market 2019-2024 ($M)
8.2 Polytherapies Market 2019-2024 ($M) - Regional Industry Research
9.North America Global Anti-Obesity Drug Market, By Type Market 2019-2024 ($M)
9.1 Prescription Drug Market 2019-2024 ($M) - Regional Industry Research
9.2 Otc Drug Market 2019-2024 ($M) - Regional Industry Research
10.South America Global Anti-Obesity Drug Market, By Drug Class Market 2019-2024 ($M)
10.1 Peripherally Acting Anti-Obesity Drug Market 2019-2024 ($M) - Regional Industry Research
10.2 Centrally Acting Anti-Obesity Drug Market 2019-2024 ($M) - Regional Industry Research
11.South America Global Anti-Obesity Drug Market, By Medication Market 2019-2024 ($M)
11.2 Polytherapies Market 2019-2024 ($M) - Regional Industry Research
12.South America Global Anti-Obesity Drug Market, By Type Market 2019-2024 ($M)
12.1 Prescription Drug Market 2019-2024 ($M) - Regional Industry Research
12.2 Otc Drug Market 2019-2024 ($M) - Regional Industry Research
13.Europe Global Anti-Obesity Drug Market, By Drug Class Market 2019-2024 ($M)
13.1 Peripherally Acting Anti-Obesity Drug Market 2019-2024 ($M) - Regional Industry Research
13.2 Centrally Acting Anti-Obesity Drug Market 2019-2024 ($M) - Regional Industry Research
14.Europe Global Anti-Obesity Drug Market, By Medication Market 2019-2024 ($M)
14.2 Polytherapies Market 2019-2024 ($M) - Regional Industry Research
15.Europe Global Anti-Obesity Drug Market, By Type Market 2019-2024 ($M)
15.1 Prescription Drug Market 2019-2024 ($M) - Regional Industry Research
15.2 Otc Drug Market 2019-2024 ($M) - Regional Industry Research
16.APAC Global Anti-Obesity Drug Market, By Drug Class Market 2019-2024 ($M)
16.1 Peripherally Acting Anti-Obesity Drug Market 2019-2024 ($M) - Regional Industry Research
16.2 Centrally Acting Anti-Obesity Drug Market 2019-2024 ($M) - Regional Industry Research
17.APAC Global Anti-Obesity Drug Market, By Medication Market 2019-2024 ($M)
17.2 Polytherapies Market 2019-2024 ($M) - Regional Industry Research
18.APAC Global Anti-Obesity Drug Market, By Type Market 2019-2024 ($M)
18.1 Prescription Drug Market 2019-2024 ($M) - Regional Industry Research
18.2 Otc Drug Market 2019-2024 ($M) - Regional Industry Research
19.MENA Global Anti-Obesity Drug Market, By Drug Class Market 2019-2024 ($M)
19.1 Peripherally Acting Anti-Obesity Drug Market 2019-2024 ($M) - Regional Industry Research
19.2 Centrally Acting Anti-Obesity Drug Market 2019-2024 ($M) - Regional Industry Research
20.MENA Global Anti-Obesity Drug Market, By Medication Market 2019-2024 ($M)
20.2 Polytherapies Market 2019-2024 ($M) - Regional Industry Research
21.MENA Global Anti-Obesity Drug Market, By Type Market 2019-2024 ($M)
21.1 Prescription Drug Market 2019-2024 ($M) - Regional Industry Research
21.2 Otc Drug Market 2019-2024 ($M) - Regional Industry Research
LIST OF FIGURES
1.US Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)2.Canada Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
3.Mexico Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
4.Brazil Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
5.Argentina Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
6.Peru Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
7.Colombia Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
8.Chile Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
9.Rest of South America Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
10.UK Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
11.Germany Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
12.France Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
13.Italy Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
14.Spain Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
15.Rest of Europe Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
16.China Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
17.India Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
18.Japan Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
19.South Korea Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
20.South Africa Anti-Obesity Drugs Market Revenue, 2019-2024 ($M)
21.North America Anti-Obesity Drugs By Application
22.South America Anti-Obesity Drugs By Application
23.Europe Anti-Obesity Drugs By Application
24.APAC Anti-Obesity Drugs By Application
25.MENA Anti-Obesity Drugs By Application
26.Arena Pharmaceuticals, Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.F. Hoffmann-La Roche Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Glaxosmithkline Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Alizyme Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Boehringer Ingelheim Gmbh, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Novo Nordisk A/S, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Pfizer Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Shionogi Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Norgine B V, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Merck Co., Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
The Anti-Obesity Drugs Market is forecast to grow at xx during the forecast period 2023-2030.
The Global Anti-Obesity Drugs Market size is estimated to be $XX Billion in 2023 and is projected to reach $xx Million by 2030.
The leading players in the Anti-Obesity Drugs Market, Alizyme Plc, Arena Pharmaceuticals Inc, Boehringer Ingelheim Gmbh, Pfizer Inc, and others.